{"id":15726,"date":"2024-02-21T10:14:13","date_gmt":"2024-02-21T09:14:13","guid":{"rendered":"https:\/\/www.bm-t.de\/?p=15726"},"modified":"2024-02-21T10:33:30","modified_gmt":"2024-02-21T09:33:30","slug":"altavo-concludes-series-a-for-the-development-of-its-artificial-voice","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2024-en\/altavo-concludes-series-a-for-the-development-of-its-artificial-voice\/","title":{"rendered":"Altavo concludes Series A for the development of its Artificial Voice"},"content":{"rendered":"

Altavo, a startup in AI-based voice reha\u00adbil\u00adi\u00adta\u00adtion founded in 2021, suc\u00adcess\u00adfully closed its Series A financ\u00ading round on Feb\u00adru\u00adary 1, 2024. A Euro\u00adpean con\u00adsor\u00adtium led by OCCIDENT is invest\u00ading \u20ac 5.0m in the devel\u00adop\u00adment of Altavo\u2019s novel Arti\u00adfi\u00adcial Voice.<\/strong><\/p>\n

Altavo\u2019s Arti\u00adfi\u00adcial Voice is a med\u00adical device designed to help voice\u00adless peo\u00adple, for exam\u00adple after laryn\u00adgec\u00adtomy or dur\u00ading mechan\u00adi\u00adcal ven\u00adti\u00adla\u00adtion, regain their own, nat\u00adural sound\u00ading voice. The pro\u00adpri\u00adetary \u201csilent speech\u201d tech\u00adnol\u00adogy, which has been devel\u00adoped in col\u00adlab\u00ado\u00adra\u00adtion with Tech\u00adni\u00adcal Uni\u00adver\u00adsity Dres\u00adden, is based on non-inva\u00adsive radar sens\u00ading and the lat\u00adest neural net architectures.<\/p>\n

Investors in the cur\u00adrent sign\u00adf\u00adi\u00adcantly over\u00adsub\u00adscribed round are, in addi\u00adtion to the lead investor OCCIDENT from Munich, Novalis Biotech (Ghent, Bel\u00adgium), bm\u2011t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen, and oth\u00aders. In addi\u00adtion, almost all seed investors from the first financ\u00ading round in Decem\u00adber 2021 are par\u00adtic\u00adi\u00adpat\u00ading with a fol\u00adlow-on invest\u00adment, among them TGFS Tech\u00adnolo\u00adgiegr\u00fcn\u00adder\u00adfonds Sach\u00adsen, High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF), Sax\u00ado\u00adnia Sys\u00adtems Hold\u00ading and TUDAG TU Dres\u00adden AG.<\/p>\n

The cur\u00adrent Series A will finance com\u00adpany growth, prod\u00aduct devel\u00adop\u00adment, the piv\u00adotal clin\u00adi\u00adcal trial, and inter\u00adna\u00adtion\u00adal\u00adiza\u00adtion. Altavo\u2019s tech\u00adnol\u00adogy not only promises to become a break\u00adthrough in the reha\u00adbil\u00adi\u00adta\u00adtion of voice\u00adless peo\u00adple, but also opens up entirely new oppor\u00adtu\u00adni\u00adties in silent com\u00admu\u00adni\u00adca\u00adtion and human-machine interfaces.<\/p>\n

\u201cWe are happy to have gained a strong Euro\u00adpean group of investors who share our vision: to help voice\u00adless peo\u00adple regain their voice. With the financ\u00ading now con\u00adcluded, our clin\u00adi\u00adcal sup\u00adport\u00aders, and our team, we see our\u00adselves excel\u00adlently posi\u00adtioned for the tech\u00adni\u00adcal and clin\u00adi\u00adcal devel\u00adop\u00adment ahead of us.\u201d<\/em>
\nRudolf von B\u00fcnau, CEO and co-founder, Altavo<\/p>\n

\u201cWith our invest\u00adment in Altavo we are bank\u00ading on an expe\u00adri\u00adenced team with a com\u00adpelling prod\u00aduct vision. As a long-term ori\u00adented investor, our ambi\u00adtion is to sup\u00adport the team on their path into the mar\u00adket and to enable the real\u00adiza\u00adtion of the company\u2019s ambi\u00adtious goals.\u201d<\/em>
\nMirco M\u00fcller, Junior Invest\u00adment Man\u00adager, OCCIDENT<\/p>\n

\u201cWe were impressed with Altavo\u2019s highly expe\u00adri\u00adenced and ded\u00adi\u00adcated team and inno\u00adv\u00ada\u00adtive, poten\u00adtially dis\u00adrup\u00adtive tech\u00adnol\u00adogy. We look for\u00adward to sup\u00adport\u00ading the com\u00adpany to bring this unique solu\u00adtion to voice-impaired individuals\u201d.<\/em>
\nJaroslav Belot\u00adserkovsky, Invest\u00adment Man\u00adager, Novalis Biotech<\/p>\n

\u201cTo us, Altavo, with its loca\u00adtions in Dres\u00adden and Jena, is a prime exam\u00adple of the inno\u00adva\u00adtion power of our cen\u00adtral Ger\u00adman region and of the suc\u00adcess\u00adful col\u00adlab\u00ado\u00adra\u00adtion between star\u00adtups and uni\u00adver\u00adsi\u00adties. We are glad to be invest\u00ading in a promis\u00ading medtech com\u00adpany that ben\u00ade\u00adfits from the exist\u00ading ecosys\u00adtems in both loca\u00adtions and com\u00adple\u00adments them.\u201d<\/em>
\nMichael Thiele, Invest\u00adment Man\u00adager, bm|t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen gmbh
\nand S\u00f6ren Schus\u00adter, CEO, TGFS Tech\u00adnolo\u00adgiegr\u00fcn\u00adder\u00adfonds Sachsen<\/p>\n

 <\/p>\n

About Altavo<\/h4>\n

Altavo GmbH<\/a> is a Dres\u00adden based med\u00adical device startup founded in Feb\u00adru\u00adary 2021. Based on non-inva\u00adsive radar sens\u00ading and arti\u00adfi\u00adcial intel\u00adli\u00adgence, Altavo is devel\u00adop\u00ading pros\u00adthet\u00adics to improve the reha\u00adbil\u00adi\u00adta\u00adtion of aphonic and severely voice impaired patients. At its Dres\u00adden and Jena loca\u00adtions, Altavo cur\u00adrently employs a team of 15 with many years of expe\u00adri\u00adence in the fields of AI \/ data sci\u00adence, speech tech\u00adnol\u00adogy, radio fre\u00adquency engi\u00adneer\u00ading, med\u00adical devices, and speech ther\u00adapy. Altavo is part\u00adner\u00ading with the Chair of Speech Tech\u00adnol\u00adogy and Cog\u00adni\u00adtive Sys\u00adtems and the Chair of Radio Fre\u00adquency Engi\u00adneer\u00ading at Tech\u00adni\u00adcal Uni\u00adver\u00adsity Dres\u00adden. The col\u00adlab\u00ado\u00adra\u00adtion is sup\u00adported by grants from the Ger\u00adman Min\u00adistry of Edu\u00adca\u00adtion and Research (BMBF) in the project \u201cPromise-AI\u201d and S\u00e4ch\u00adsis\u00adche Auf\u00adbaubank (SAB) in the project \u201cSEMECO-B3: MUSIK\u201d.
\nMedia Con\u00adtact: Rudolf von B\u00fcnau, rudolf.vonbuenau@altavo.eu<\/p>\n

About OCCIDENT<\/h4>\n

OCCIDENT<\/a> is an inter\u00adna\u00adtional ven\u00adture cap\u00adi\u00adtal investor with offices in Munich and Zug, is own\u00ader\u00adman\u00adaged and invests its own assets. Its mis\u00adsion is to make a pos\u00adi\u00adtive con\u00adtri\u00adbu\u00adtion to soci\u00adety through sus\u00adtain\u00adable and mean\u00ading\u00adful invest\u00adments. OCCIDENT invests in inno\u00adv\u00ada\u00adtive deep tech start-ups with excel\u00adlent tech\u00adnolo\u00adgies, broad appli\u00adca\u00adtion pos\u00adsi\u00adbil\u00adi\u00adties and the poten\u00adtial for fur\u00adther value-gen\u00ader\u00adat\u00ading devel\u00adop\u00adment in the fields of life sci\u00adences, indus\u00adtrial tech and dig\u00adi\u00adtal. OCCIDENT acts as a long-term enabler for highly inno\u00adv\u00ada\u00adtive star\u00adtups and vision\u00adary founders.<\/p>\n

About Novalis Biotech<\/h4>\n

Novalis Biotech<\/a> (Ghent, Bel\u00adgium) is an early-stage ven\u00adture cap\u00adi\u00adtal investor in tech\u00adnolo\u00adgies that rev\u00ado\u00adlu\u00adtion\u00adize health\u00adcare. The company\u2019s core com\u00adpe\u00adtence lies in dig\u00adi\u00adtal\u00adiza\u00adtion in the life sci\u00adences with a focus on bioin\u00adfor\u00admat\u00adics, genomics and diag\u00adnos\u00adtics. Novalis strongly believes in apply\u00ading inno\u00adv\u00ada\u00adtive enabling tech\u00adnol\u00adogy to advance the pre\u00adven\u00adtion, diag\u00adno\u00adsis, or treat\u00adment of a disease.<\/p>\n

About bm|t beteiligungsmanagement th\u00fcringen<\/h4>\n

bm|t<\/a>, based in Erfurt, is a sub\u00adsidiary of Th\u00fcringer Auf\u00adbaubank and the lead\u00ading address for invest\u00adments in Thuringia. bm | t cur\u00adrently man\u00adages twelve funds with a total vol\u00adume of around EUR 445 mil\u00adlion, which are to be invested in inno\u00adv\u00ada\u00adtive com\u00adpa\u00adnies in almost all sec\u00adtors and in all phases of cor\u00adpo\u00adrate devel\u00adop\u00adment \u2014 both in the start-up and growth phases or in com\u00adpany suc\u00adces\u00adsion situations.
\nMedia Con\u00adtact: Michael Thiele<\/a>, michael.thiele@bm\u2011t.com<\/p>\n

About TGFS Technologiegr\u00fcnderfonds Sachsen<\/h4>\n

TGFS<\/a> is an equity investor for knowl\u00adedge-based, tech\u00adnol\u00adogy-ori\u00adented start-ups in the fed\u00aderal state of Sax\u00adony. It is the lead\u00ading start-up investor in Sax\u00adony and pro\u00advides teams in the seed and start-up phases with ven\u00adture cap\u00adi\u00adtal and man\u00adage\u00adment sup\u00adport. More\u00adover, an invest\u00adment by TGFS opens up access to fur\u00adther inter\u00adna\u00adtional investors from the fund\u2019s net\u00adwork. The fund was first launched in 2008 by Saxony\u2019s Gov\u00adern\u00adment (includ\u00ading ERDF fund\u00ading) and Saxon finan\u00adcial insti\u00adtu\u00adtions and has since sup\u00adported over 100 start-ups in what is now the third fund generation.
\nMedia Con\u00adtact: S\u00f6ren Schus\u00adter, ph. +49 172 2001097, soeren.schuster@cfh.de<\/p>\n

About High-Tech Gr\u00fcnderfonds<\/h4>\n

The seed investor High-Tech Gr\u00fcn\u00adder\u00adfonds<\/a> (HTGF) finances tech start-ups with growth poten\u00adtial and has sup\u00adported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 bil\u00adlion euros under man\u00adage\u00adment. Its team of expe\u00adri\u00adenced invest\u00adment man\u00adagers and start-up experts sup\u00adport young com\u00adpa\u00adnies with exper\u00adtise, entre\u00adpre\u00adneur\u00adial spirit and pas\u00adsion. HTGF\u2019s focus is on high-tech start-ups in the fields of dig\u00adi\u00adtal tech, indus\u00adtrial tech, life sci\u00adences, chem\u00adistry and related busi\u00adness areas. To date, exter\u00adnal investors have injected about 5 bil\u00adlion euros of cap\u00adi\u00adtal into the HTGF port\u00adfo\u00adlio via more than 2,000 fol\u00adlow-on financ\u00ading rounds. In addi\u00adtion, HTGF has already suc\u00adcess\u00adfully sold shares in more than 170 com\u00adpa\u00adnies. Fund investors in this pub\u00adlic-pri\u00advate part\u00adner\u00adship include the Ger\u00adman Fed\u00aderal Min\u00adistry for Eco\u00adnomic Affairs and Cli\u00admate Action, KfW Cap\u00adi\u00adtal and 45 com\u00adpa\u00adnies from a wide range of industries.
\nMedia Con\u00adtact: Tobias Jacob, Senior Mar\u00adket\u00ading & Com\u00admu\u00adni\u00adca\u00adtions Manager
\nph. +49 228 82300 121, t.jacob@htgf.de<\/p>\n","protected":false},"excerpt":{"rendered":"

Altavo, a startup in AI-based voice reha\u00adbil\u00adi\u00adta\u00adtion, suc\u00adcess\u00adfully closed its Series A financ\u00ading round of \u20ac 5.0m.<\/p>\n","protected":false},"author":2,"featured_media":15723,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[248],"tags":[176,177,210,159,171,175,174],"class_list":["post-15726","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2024-en","tag-bm-t-en","tag-bmt-en","tag-investeepartner","tag-investment-en","tag-thuringia","tag-thuringia-growth-fund","tag-wbf-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/15726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=15726"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/15726\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/15723"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=15726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=15726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=15726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}